The European Medicines Agency (EMA) has urged healthcare professionals to pay attention to signs of diabetic ketoacidosis (DKA) in people with type 2 diabetes who are taking SGLT2 inhibitors.

These drugs available under the trade names Forxiga (dapagliflozin), Invokana (canagliflozin) and Jardiance (empagliflozin), are designed to lower blood glucose levels in people with type 2 diabetes.

Since mid-2015, there have been concerns that SGLT2 inhibitors are a risk factor for DKA in people with type 2 diabetes. In a study published in the journal Diabetes Care identified "an increased risk of diabetic ketoacidosis with uncharacteristically mild to moderate glucose elevations... associated with the use of all the approved [SGLT2 inhibitors]." In other words, these cases of DKA were not associated with significantly elevated blood glucose levels; this phenomenon is known as euglycemic diabetic ketoacidosis.

The safety concerns surrounding SGLT2 inhibitors prompted the US Food and Drug Administration (FDA) to issue a notice. Shortly after, the EMA conducted its own review, through which it identified that more than 100 people taking SGLT2 inhibitors had developed DKA. The EMA has now released a statement in which it advises doctors to look out for symptoms of DKA in people with type 2 diabetes taking SGLT2 inhibitors, even if they don't have high blood glucose levels. It lists the symptoms and explains the risk factors associated with DKA.

However, the statement also points out that the benefits of SGLT2 inhibitors - Forxiga, Invokana and Jardiance - consistently outweigh the relatively slim risk of DKA. Although SGLT2 treatment should be discontinued immediately if you show signs of DKA, you should carry on adhering to the treatment.

Read More